Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Integra Lifesciences Holdings 5-Day RSI Related Terms
IART vs ATEC, AHCO, INSP: 5-Day RSI Comparison
For the Medical Devices subindustry, Integra Lifesciences Holdings's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integra Lifesciences Holdings 5-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's 5-Day RSI distribution charts can be found below:
* The bar in red indicates where Integra Lifesciences Holdings's 5-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integra Lifesciences Holdings (IART) has a 5-Day RSI of 65.09 as of Jul. 16, 2026. According to the industry distribution chart, Integra Lifesciences Holdings ranks #667 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 77%.
Is Integra Lifesciences Holdings' 5-Day RSI too high?
Integra Lifesciences Holdings' current 5-Day RSI is 65.09. The Medical Devices & Instruments industry median 5-Day RSI is 50.35. Integra Lifesciences Holdings' value of 65.09 is 29.3% above this industry median. Based on the distribution chart, Integra Lifesciences Holdings ranks #667 out of 866 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Integra Lifesciences Holdings has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integra Lifesciences Holdings' 5-Day RSI compare to ATEC and AHCO?
According to the Medical Devices & Instruments industry distribution chart, Integra Lifesciences Holdings ranks #667 out of 866 companies for 5-Day RSI. This places Integra Lifesciences Holdings in the lower half of its industry. The industry median 5-Day RSI is 50.35. Integra Lifesciences Holdings' value of 65.09 is 29.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Day RSI for a Medical Devices & Instruments company?
The median 5-Day RSI among Medical Devices & Instruments companies is 50.35, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a 5-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 5-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integra Lifesciences Holdings's current 5-Day RSI of 65.09 is 29.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Day RSI mean?
A high 5-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 5-Day RSI is 50.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integra Lifesciences Holdings's current 5-Day RSI is 65.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integra Lifesciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integra Lifesciences Holdings (IART) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.81, compared to a current price of $18.78 — trading 21.1% below its estimated fair value. The current 5-Day RSI is 65.09 and 29.3% above the Medical Devices & Instruments industry median of 50.35. Integra Lifesciences Holdings' overall GF Score™ is 70/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Day RSI calculated?
5-Day RSI is calculated from a company's financial statements. For Integra Lifesciences Holdings (IART), the current 5-Day RSI is 65.09 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integra Lifesciences Holdings (IART) Overvalued in 2026?
Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued.
The current stock price of $18.78 is trading 21.1% below its estimated GF Value™ of $23.81.
GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.
Key valuation signals for IART:
5-Day RSI: 65.09
GF Value™: $23.81 vs. price of $18.78 (21.1% below fair value)
Industry Position: 29.3% above the Medical Devices & Instruments median (#667 of 866)
No single metric tells the full story. See the IART stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integra Lifesciences Holdings Business Description
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
70GF Score
Get the complete analysis for IART
5-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IART has been successfully added to your 
